1 Stock to Buy This Week and 1 Stock to Dump

NASDAQ: VRTX | Vertex Pharmaceuticals Inc. News, Ratings, and Charts

VRTX – Investors’ sentiment is significantly mixed at the moment, with market volatility at its peak. It could be wise to buy quality stock Vertex Pharmaceuticals (VRTX), which possesses robust financials. However, fundamentally weak stock NeoGenomics (NEO) is best avoided now. Read on….

Amid sky-high inflation and consecutive rate hikes, the U.S. GDP slumped 0.9% in the second quarter, following a 1.6% contraction in the first quarter. However, many, including President Biden, have refused to tag this as a recession as of now. He said, “If you look at our job market, consumer spending, business investment, we see signs of economic progress in the second quarter, as well.”

On the other hand, July was the best month for Wall Street investors since November 2020, with the S&P 500 gaining 9.1% in the month. The market was buoyed by large companies posting better-than-expected financial results.

Nonetheless, market volatility is palpable and seems to concern the broader markets. The CBOE Volatility Index has gained 32.9% year-to-date.

Given the backdrop, it could be wise to scoop up the quality stock Vertex Pharmaceuticals Incorporated (VRTX), which possesses robust financials. However, fundamentally weak stock NeoGenomics, Inc. (NEO) might be best avoided now.

Stock to Buy:

Vertex Pharmaceuticals Incorporated (VRTX)

Biotechnology company, VRTX, develops and commercializes therapies for treating cystic fibrosis. VRTX also works with investigational small molecules, cell, and genetic therapies, for other serious diseases like sickle cell disease, beta-thalassemia, type 1 diabetes, and others.

On July 11, 2022, VRTX entered into a definitive agreement to acquire ViaCyte, a privately held biotechnology company engaged in delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes, for $320 million in cash. This could be a major boost for type 1 diabetes treatment worldwide.

Moreover, VRTX and Verve Therapeutics, Inc. (VERV) announced an exclusive, four-year global research collaboration to develop an in vivo gene editing program for single undisclosed liver disease. VRTX is expected to be responsible for subsequent development, manufacturing, and commercialization of any program stemming from VERV’s research.

For the first quarter ended March 31, 2022, VRTX’s net product revenues increased 21.7% year-over-year to $2.10 billion. Its non-GAAP net income came in at $907 million, up 16.1% year-over-year, while its non-GAAP EPS came in at $3.52, up 18.1% year-over-year. Also, its non-GAAP operating income came in at $1.17 billion, up 16.5% year-over-year.

Analysts expect VRTX’s revenue to be $8.58 billion in 2022, representing a 13.2% year-over-year increase. The company’s EPS is expected to grow 9% year-over-year to $14.19 in 2022. In addition, it has surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 39.9% to close the last trading session at $280.41.

VRTX’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, equating to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

VRTX has an A grade for Quality and a B grade for Growth and Value. It is ranked first among 402 stocks in the Biotech industry. Click here for the additional POWR Ratings for Momentum, Stability, and Sentiment for VRTX.

Stock to Avoid:

NeoGenomics, Inc. (NEO)

NEO operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company provides one of the world’s most comprehensive oncology-focused testing menus. It operates through Clinical Services and Pharma Services segments.

NEO’s total net revenue increased marginally year-over-year to $117.17 million for the first quarter ended March 31, 2022. However, its pharma services revenue came in at $18.38 million, down 3.5% year-over-year. Furthermore, its net loss increased 123.4% year-over-year to $49.41 million, while its loss per share increased 110.5% year-over-year to $0.40.

NEO’s EPS is estimated to fall 192.6% year-over-year to a negative $0.79 in 2022. Its EPS is expected to remain negative in 2023. The stock has lost 77.9% over the past year to close the last trading session at $10.12.

NEO’s POWR Ratings reflect its poor prospects. The stock has an overall F rating, equating to a Strong Sell. It has an F grade for Growth and a D for Value and Momentum.

Click here to access the additional POWR Ratings for NEO (Stability, Sentiment, and Quality). Also, NEO is ranked #51 out of 54 stocks in the D-rated Medical – Diagnostics/Research industry.


VRTX shares were trading at $277.39 per share on Monday morning, down $3.02 (-1.08%). Year-to-date, VRTX has gained 26.32%, versus a -12.35% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
VRTXGet RatingGet RatingGet Rating
NEOGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Is the Bear Market Over???

The S&P 500 (SPY) quickly dispensed with 2 key levels of resistance on Wednesday following statements by Fed Chairman Powell. Now more people are contemplating that the 2022 bear market may be over and time to get more bullish. 40 year investment veteran Steve Reitmeister weighs in on this timely topic in his new commentary. Spoiler Alert: he is not impressed and still believes that the bears have the upper hand. Read on below for the full story...

:  |  News, Ratings, and Charts

1 Momentum Stock to Buy Now for Extraordinary Gains in 2023

Valero Energy (VLO) expanded its production for the fourth quarter anticipating increased demand. The stock is up nearly 70% in 2022. It is trading above its 50-day and 200-day moving averages. As this momentum is expected to remain, investors should consider buying VLO for continued gains in 2023. Read on…

:  |  News, Ratings, and Charts

3 Stocks Every Investor Should Add to Their Watchlist This Week

With significant growth registered in the third quarter, investor confidence has been uplifted. Hence, quality stocks with solid growth prospects, such as Amgen (AMGN), Cognizant Technology Solutions (CTSH), and Dole plc (DOLE), could be added to the watchlist this week. Read on…

:  |  News, Ratings, and Charts

1 Stable Stock Warren Buffett Owns and You Should Too

World-famous investor Warren Buffett picked up shares of healthcare services provider McKesson Corporation (MCK) this year. The company has raised its dividends for 16 consecutive years. With a recession expected next year, this healthcare services stock is expected to remain stable as demand for healthcare and related services usually remain unaffected regardless of economic conditions. Thus, investors may consider buying the stock now. Read more…

:  |  News, Ratings, and Charts

3 Stocks Every Investor Should Add to Their Watchlist This Week

With significant growth registered in the third quarter, investor confidence has been uplifted. Hence, quality stocks with solid growth prospects, such as Amgen (AMGN), Cognizant Technology Solutions (CTSH), and Dole plc (DOLE), could be added to the watchlist this week. Read on…

Read More Stories

More Vertex Pharmaceuticals Inc. (VRTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VRTX News